Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS, Oon ML, Wang S, Tan SY, Ng SB.
Pathology. 2020 Jan;52(1):111-127. doi: 10.1016/j.pathol.2019.09.011. Epub 2019 Nov 22.
Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M, Bister A, Haist C, Thivakaran A, Cengiz SC, Sendker S, Bartels N, Thomitzek A, Smorra D, Hejazi M, Uhrberg M, Scheckenbach K, Monzel C, Wiek C, Reinhardt D, Niktoreh N, Hanenberg H.
Front Immunol. 2022 Apr 7;13:847008. doi: 10.3389/fimmu.2022.847008. eCollection 2022.
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A.
Science. 2002 Mar 15;295(5562):2097-100. doi: 10.1126/science.1068440.
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N, Zhang C, Zhang Y, Fan Y, Zhang J, Lin X, Guo T, Gu Y, Wu J, Gao J, Zhao X, He Z.
J Transl Med. 2024 Mar 13;22(1):274. doi: 10.1186/s12967-024-04990-6.
Key candidate genes and pathways in T lymphoblastic leukemia/lymphoma identified by bioinformatics and serological analyses.
Ren Y, Liang H, Huang Y, Miao Y, Li R, Qiang J, Wu L, Qi J, Li Y, Xia Y, Huang L, Wang S, Kong X, Zhou Y, Zhang Q, Zhu G.
Front Immunol. 2024 Feb 23;15:1341255. doi: 10.3389/fimmu.2024.1341255. eCollection 2024.
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.
Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, Fröse J, Goulet D, Gordon KS, Eidell KP, Leclerc P, Whittaker CA, Larson RC, Muscato AJ, Yates KB, Dubrot J, Doench JG, Regev A, Vander Heiden MG, Maus MV, Manguso RT, Birnbaum ME, Hemann MT.
Nat Commun. 2023 Dec 5;14(1):8048. doi: 10.1038/s41467-023-43790-2.
CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, Gao L, Li Y, Luo L, Li G, Li Z, Li S, He J, Zhang L, Chen L, Huang W, Yin P, Li C, Li X, Wang Y, Dong Y, Zhang D, Zang Q, Chen Y, Shen L, Li W, Cao W, Zhang X, Wang S.
Leukemia. 2023 Nov;37(11):2176-2186. doi: 10.1038/s41375-023-02018-4. Epub 2023 Sep 12.
Leukemia and lymphoma of natural killer lineage cells.
Oshimi K.
Int J Hematol. 2003 Jul;78(1):18-23. doi: 10.1007/BF02983235.
Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.
Kumar A, Taghi Khani A, Duault C, Aramburo S, Sanchez Ortiz A, Lee SJ, Chan A, McDonald T, Huang M, Lacayo NJ, Sakamoto KM, Yu J, Hurtz C, Carroll M, Tasian SK, Ghoda L, Marcucci G, Gu Z, Rosen ST, Armenian S, Izraeli S, Chen CW, Caligiuri MA, Forman SJ, Maecker HT, Swaminathan S.
J Immunother Cancer. 2023 May;11(5):e006649. doi: 10.1136/jitc-2022-006649.
